Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€29.20

€29.20

-
-
-
€31.82

€31.82

 
19.12.20 / Tradegate WKN: A14X6J / Name: Aimmune / Stock / Pharmaceuticals / Small Cap /
Latest predictions
€20.00
14.03.20
124.62%
buy
€30.00
06.09.19
51.45%
buy
€31.57
13.06.19
62.35%
buy
€36.08
06.06.19
60.82%
buy
€32.06
18.05.18
6.31%
buy
Best running prediction
€20.00
14.03.20
124.62%
buy
Your prediction

Aimmune Therapeutics Inc Stock

Our community is currently high on Aimmune Therapeutics Inc with 5 Buy predictions and 0 Sell predictions.
As a result the target price of €31.00 shows a slightly positive potential of 6.164% compared to the current price of €29.20 for Aimmune Therapeutics Inc.

Pros and Cons of Aimmune Therapeutics Inc in the next few years

Pros
?
Market Position
?
Conscious of the environment
?
Growth compared to competition
Cons
?
Brand
?
Shareholder structure
?
Worthwhile Investment for the next years
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Aimmune Therapeutics Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Aimmune Therapeutics Inc - - - - - - -
Cocrystal Pharma Inc. -8.110% -5.310% 15.054% -7.759% -7.759% - -
Vericel Corp. 0.970% 8.787% 19.816% 298.467% 117.391% 427.919% 1896.161%
Assembly Biosciences Inc. -2.330% - - - - - -

Comments

Sell Aimmune Therapeutics Inc
Show more

Prediction Sell
Perf. (%) 26.09%
Target price
Change
Ends at 23.12.19

Sell beendet
Show more

Sell Aimmune Therapeutics Inc
Show more

Other discussions about Aimmune Therapeutics Inc Stock

Trading Aimmune Therapeutics Inc

Trading Aimmune Therapeutics Inc

New thread Forum

News

Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years: https://mms.businesswire.com/media/20201220005027/en/848174/5/AIMMUNE-Logo2020-RGB.jpg
Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years


Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled